黄芪甲苷纳米结构脂质载体冻干粉的制备及其初步质量评价
Preparation and preliminary characterization of lyophilized astragaloside IV-loaded nanostructured lipid carriers
作者:陈佳;龚涛;
Author:
收稿日期: 年卷(期)页码:2011,26(06):-530-533
期刊名称:华西药学杂志
Journal Name:WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字:黄芪甲苷;纳米结构脂质载体;包封率;冷冻干燥
Key words:
基金项目:
中文摘要
目的制备黄芪甲苷纳米结构脂质载体(AST-NLC),初步研究其冻干工艺,并考察其理化性质。方法采用薄膜-超声分散法制备AST-NLC;选用不同冻干保护剂制备AST-NLC冻干粉末,以外观、色泽、再分散性、粒径和PDI为综合指标,优选保护剂的种类和浓度,拟定冻干工艺;考察AST-NLC的形态和冻干前后的粒径分布、Zeta电位、包封率及载药量。结果以10%的蔗糖作为冻干保护剂、-40℃超低温冰箱中预冻4 h后,迅速放入冷冻干燥机中冷冻干燥24 h,所得冻干粉末的外观、色泽、再分散性均较好;AST-NLC在透射电镜下呈球形;冻干前(后)的平均粒径为104.3±1.25 nm(144.1±17.08nm),PDI为0.118±0.033(0.132±0.055),Zeta电位为-7.00±0.35 mV(-11.2±0.9 mV),包封率为94.37%±0.39%(96.60%±0.45%),载药量为2.80%±0.02%(2.60%±0.05%)。结论所用AST-NLC的制备工艺简便,制得的AST-NLC包封率较高;采用优化后的冻干工艺可得到令人满意的AST-NLC冻干粉末。
参考文献
[1]Zhuang CY,Li N,Wang M,et al.Preparation and characterizationof vinpocetine loaded nanostructured lipid carriers(NLC)forimproved oral bioavailability[J].Int J Pharm,2010,394:179-185.
[2]胥娜,钟文英,朱丹妮.固体脂质纳米粒在提高难溶性药物生物利用度中的应用[J].中华中医药学刊,2007,25(8):1605-1607.
[3]叶志义,刘巧莲.脂质纳米粒子在药物中的应用[J].生命科学,2009,21(3):456-460.
[4]阮婧华,肖吉娇,朱迪,等.口服槲皮素纳米结构脂质载体的制备及体外评价[J].华西药学杂志,2010,25(4):403-405.
[5]石海莲,吴大正,胡之璧.黄芪皂苷甲的研究进展[J].中国药学杂志,2008,43(8):565-567.
[6]宋晓东,刘哲,辛颖,等.HPLC-ELSD测定芪红胶囊中的黄芪甲苷[J].华西药学杂志,2008,23(2):209-210.
[7]Huang CR,Wang GF,Wu XL,et al.Absorption enhancementstudy of astragaloside IV based on its transport mechanism in Ca-co-2 cells[J].Eur J Drug Metab Pharmacokinet,2006,31(1):5-10.
[8]Du Y,Zhang Q,Chen GG,et al.Pharmacokinetics of astragalosideIV in rats by liquid chromatography coupled with tandem massspectrometry[J].Eur J Drug Metab Pharmacokinet,2005,30(4):269-273.
【关闭】